FDA/CDC

FDA okays new CAR T therapy, first for mantle cell lymphoma


 

The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (Tecartus, Kite Pharma), the first approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

The new agent is the second approved CAR T cell product developed by Kite and follows the 2017 approval of axicabtagene ciloleucel (Yescarta) for diffuse large B-cell lymphoma.

“Despite promising advances, there are still major gaps in treatment for patients with MCL who progress following initial therapy,” investigator Michael Wang, MD, of the University of Texas MD Anderson Cancer Center in Houston, said in a company statement. “Many patients have high-risk disease and are more likely to keep progressing, even after subsequent treatments.”

In the same press statement, Meghan Gutierrez, chief executive officer, Lymphoma Research Foundation, said: “This approval marks the first CAR T cell therapy approved for mantle cell lymphoma patients and represents a new frontier in the treatment of this disease.”

The approval of the single-infusion therapy is based on efficacy and safety data from the ongoing, single-arm ZUMA-2 pivotal trial, which enrolled 74 adult patients. All patients had previously received anthracycline- or bendamustine-containing chemotherapy, an anti-CD20 antibody therapy and a Bruton tyrosine kinase inhibitor (ibrutinib or acalabrutinib).

In the trial, there was an objective response rate, which was the primary outcome measure, of 87% among 60 patients who were evaluable for efficacy analysis; 62% had a complete response.

Among all patients, follow-up was at least 6 months after their first objective disease response. Median duration of response has not yet been reached.

In terms of adverse events, 18% of the 82 patients evaluable for safety experienced > grade 3 cytokine release syndrome and 37% experienced neurologic events, per the company statement. The most common (≥ 10%) grade 3 or higher adverse reactions were anemia, neutropenia, thrombocytopenia, hypotension, hypophosphatemia, encephalopathy, leukopenia, hypoxia, pyrexia, hyponatremia, hypertension, infection-pathogen unspecified, pneumonia, hypocalcemia, and lymphopenia.

Brexucabtagene autoleucel will be manufactured in Kite’s facility in California. In the pivotal trial, there was a 96% manufacturing success rate and a median manufacturing turnaround time of 15 days from leukapheresis to product delivery.

A version of this article originally appeared on Medscape.com.

Recommended Reading

FDA approves Brukinsa for relapsed, refractory MCL
B-Cell Lymphoma ICYMI
Acalabrutinib may outperform other targeted therapies in MCL
B-Cell Lymphoma ICYMI
SOX11 shows value as diagnostic marker in MCL
B-Cell Lymphoma ICYMI
The clinical impact of new approvals in sickle cell, MCL
B-Cell Lymphoma ICYMI
Orelabrutinib could be ‘preferred’ BTK inhibitor for MCL
B-Cell Lymphoma ICYMI
KTE-X19 produces highest response rate in MCL subgroup
B-Cell Lymphoma ICYMI
Some MCL patients can safely stop venetoclax-ibrutinib, study suggests
B-Cell Lymphoma ICYMI
LOXO-305: Next-gen BTK inhibitor safe and effective in B-cell malignancies
B-Cell Lymphoma ICYMI
Experts break down latest CAR T-cell advances in lymphoma
B-Cell Lymphoma ICYMI
COVID-19: Experts hasten to head off mental health crisis
B-Cell Lymphoma ICYMI